Predicted to be involved in several processes, including cellular response to cytokine stimulus; cellular response to lipid; and hematopoietic stem cell differentiation. Orthologous to human MIR155 (microRNA 155); INTERACTS WITH 2-acetamidofluorene; cisplatin; clofibrate.
[Tretinoin co-treated with Phenylbutyrates co-treated with 1-hydroxy-2-oxo-3, 3-bis(2-aminoethyl)-1-triazene] results in decreased expression of MIR155 mRNA
MIR155 promotes the reaction [arsenite results in decreased expression of NFE2L2 mRNA], MIR155 promotes the reaction [arsenite results in decreased expression of NFE2L2 protein]
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides]] which results in increased expression of MIR155 mRNA
[[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MIR155 mRNA] which results in decreased expression of CEBPB protein more ...
MIR155 gene mutant form promotes the reaction [Cisplatin results in increased expression of FOS mRNA], MIR155 gene mutant form promotes the reaction [Cisplatin results in increased expression of FOS protein]
[[[cypermethrin results in decreased expression of MIR155 mRNA] which results in increased expression of BCL6 mRNA] which results in decreased expression of MAP2K4 protein] which results in decreased phosphorylation of and results in decreased activity of MAPK8 protein more ...
[Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary] results in increased expression of MIR155 mRNA, Metformin inhibits the reaction [[Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary] results in increased expression of MIR155 mRNA]
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides]] which results in increased expression of MIR155 mRNA
[[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MIR155 mRNA] which results in decreased expression of CEBPB protein more ...
[[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MIR155 mRNA] which results in decreased expression of CEBPB protein more ...
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of MIR155 mRNA], Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of MIR155 mRNA]
Metformin inhibits the reaction [[Desoxycorticosterone Acetate co-treated with Sodium Chloride, Dietary] results in increased expression of MIR155 mRNA]
MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]], Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]
MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]] more ...
[Air Pollutants results in increased abundance of [Particulate Matter co-treated with Carbon co-treated with Sulfur Dioxide co-treated with Nitrogen Oxides]] which results in increased expression of MIR155 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
